Newer, more expensive psoriasis drugs only slightly more effective than older therapies under real world conditions

More expensive biologic treatments for psoriasis were only marginally more effective than standard treatments, according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania. Researchers found that previously reported response rates from randomized controlled trials were higher than results in a clinical, real-world setting. The research was published in the Archives of Dermatology, one of the JAMA/Archives Journals.

The researchers found that biologics were slightly more effective than a standard drug treatment for , methotrexate, but that their impact was less then what has been reported in clinical trials which study efficacy of a medication under idealized circumstances and only for a short period of treatment.

"When one looks at the outcome as being clear, or almost clear [skin], the biologics appear to be more effective than methotrexate," said study author Joel Gelfand, MD, assistant professor of and Epidemiology. But, when total body surface area affected by the disease is added in that difference diminishes, he said. More importantly, patients noted no differences in health related quality of life with the newer biologic medications compared to which has been used for psoriasis for over 40 years.

Gelfand noted that while the newer biologics are generally tolerated better by patients, with fewer side effects that lead to stopping the medication, their effectiveness diminishes with time. Traditional treatments may cause nausea and other potential side effects. Since psoriasis is a life-long disease, patients on biologics are often left with only a relatively short period of optimum control of their psoriasis.

Biologics can cost $10,000 to $20,000 a year, compared to a couple of thousand dollars for older drugs or , said Gelfand.

Related Stories

Study compares effectiveness of psoriasis treatments

Apr 20, 2012

(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of ...

Costs of psoriasis treatments outpace inflation

Jan 18, 2010

Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic ...

Recommended for you

Depression tied to worse lumbar spine surgery outcomes

2 hours ago

(HealthDay)—Depressive symptoms are associated with poorer long-term outcome in patients undergoing surgery for lumbar spinal stenosis (LSS), according to research published in the Oct. 1 issue of The Sp ...

Ebola death toll edging to 4,900 mark: WHO

2 hours ago

The death toll in the world's worst-ever Ebola outbreak has edged closer to 4,900, while almost 10,000 people have now been infected, new figures from the World Health Organization showed Wednesday.

US to track everyone coming from Ebola nations

3 hours ago

U.S. authorities said Wednesday that everyone traveling into the U.S. from Ebola-stricken nations will be monitored for symptoms for 21 days. That includes returning American aid workers, federal health employees ...

US: Monitoring for all coming from Ebola nations

5 hours ago

U.S. health officials said Wednesday that they would begin monitoring all travelers—even Americans—who come to the U.S. from Ebola-stricken West African nations for 21 days, significantly expanding their vigilance.

User comments